Michele Pier Luca Guarino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8772779/publications.pdf

Version: 2024-02-01

60 papers 2,473 citations

230014 27 h-index 232693 48 g-index

60 all docs

60 docs citations

60 times ranked

3001 citing authors

#	Article	IF	CITATIONS
1	Association between Dietary Habits and Fecal Microbiota Composition in Irritable Bowel Syndrome Patients: A Pilot Study. Nutrients, 2021, 13, 1479.	1.7	15
2	Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms. Nutrients, 2021, 13, 1506.	1.7	48
3	The Results From Up-Front Esophageal Testing Predict Proton Pump Inhibitor Response in Patients With Chronic Cough. American Journal of Gastroenterology, 2021, 116, 2199-2206.	0.2	14
4	Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy. Frontiers in Medicine, 2021, 8, 655474.	1.2	6
5	The impact of the intestinal microbiota and the mucosal permeability on three different antibiotic drugs. European Journal of Pharmaceutical Sciences, 2021, 164, 105869.	1.9	3
6	Post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance predict PPI response in GERD patients with extra esophageal symptoms. Digestive and Liver Disease, 2020, 52, 173-177.	0.4	22
7	Role of Overweight and Obesity in Gastrointestinal Disease. Nutrients, 2020, 12, 111.	1.7	59
8	Understanding the relationship between esophageal motor disorders and reflux disease. Expert Review of Gastroenterology and Hepatology, 2020, 14, 933-940.	1.4	3
9	Palmitic Acid Affects Intestinal Epithelial Barrier Integrity and Permeability In Vitro. Antioxidants, 2020, 9, 417.	2.2	23
10	Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients, 2020, 12, 372.	1.7	127
10		1.7	127
	Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients, 2020, 12, 372. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults.		
11	Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients, 2020, 12, 372. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients, 2020, 12, 1037.	1.7	108
11 12	Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients, 2020, 12, 372. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients, 2020, 12, 1037. Leonardo da Vinci's advice on public health. Lancet, The, 2020, 395, e16. Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease.	1.7 6.3	108
11 12 13	Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients, 2020, 12, 372. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients, 2020, 12, 1037. Leonardo da Vinci's advice on public health. Lancet, The, 2020, 395, e16. Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Frontiers in Microbiology, 2019, 10, 1655. New classifications of gastroesophageal reflux disease: an improvement for patient management?.	1.7 6.3 1.5	108 2 146
11 12 13	Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients, 2020, 12, 372. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients, 2020, 12, 1037. Leonardo da Vinci's advice on public health. Lancet, The, 2020, 395, e16. Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Frontiers in Microbiology, 2019, 10, 1655. New classifications of gastroesophageal reflux disease: an improvement for patient management?. Expert Review of Gastroenterology and Hepatology, 2019, 13, 761-769.	1.7 6.3 1.5	108 2 146 11
11 12 13 14	Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients, 2020, 12, 372. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients, 2020, 12, 1037. Leonardo da Vinci's advice on public health. Lancet, The, 2020, 395, e16. Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Frontiers in Microbiology, 2019, 10, 1655. New classifications of gastroesophageal reflux disease: an improvement for patient management?. Expert Review of Gastroenterology and Hepatology, 2019, 13, 761-769. Leonardo's folio 730 recto: lessons for the medical humanities. Lancet, The, 2019, 393, 1411-1412. A case of hepatitis B virus infection in Eritrean Diciotti migrant: phylogenetic analysis and â€mirror	1.7 6.3 1.5 1.4	108 2 146 11

#	Article	IF	CITATIONS
19	Gut mucosal-associated microbiota better discloses inflammatory bowel disease differential patterns than faecal microbiota. Digestive and Liver Disease, 2019, 51, 648-656.	0.4	67
20	Impairment of GH/IGF-1 Axis in the Liver of Patients with HCV-Related Chronic Hepatitis. Hormone and Metabolic Research, 2018, 50, 145-151.	0.7	12
21	Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy. Digestive and Liver Disease, 2017, 49, 495-499.	0.4	22
22	Origin and evolutionary dynamics of Hepatitis B virus (HBV) genotype E in Madagascar. Pathogens and Global Health, 2017, 111, 23-30.	1.0	2
23	PD-L1/PD-1 check-point in gastric carcinoma with lymphoid stroma case report with immunochemical study. Medicine (United States), 2017, 96, e5730.	0.4	4
24	First epidemiological and phylogenetic analysis of Hepatitis B virus infection in migrants from Mali. Journal of Medical Virology, 2017, 89, 639-646.	2.5	6
25	Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility. Neurogastroenterology and Motility, 2017, 29, e12928.	1.6	12
26	Effect of Inulin on Proteome Changes Induced by Pathogenic Lipopolysaccharide in Human Colon. PLoS ONE, 2017, 12, e0169481.	1.1	15
27	Asymptomatic Parasitic Infection in a Crohn's Disease Patient on Anti-TNFα Therapy: An Alert for Our Patients?. Journal of Crohn's and Colitis, 2016, 10, 1455-1456.	0.6	4
28	Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota. World Journal of Gastroenterology, 2016, 22, 9871.	1.4	24
29	Eosinophilic esophagitis: New insights in pathogenesis and therapy. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 66.	0.6	16
30	Starring role of toll-like receptor-4 activation in the gut-liver axis. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 99.	0.5	42
31	Antioxidant Activity of Inulin and Its Role in the Prevention of Human Colonic Muscle Cell Impairment Induced by Lipopolysaccharide Mucosal Exposure. PLoS ONE, 2014, 9, e98031.	1.1	66
32	Acid reflux episodes sensitize the esophagus to perception of weakly acidic and mixed reflux in nonâ€erosive reflux disease patients. Neurogastroenterology and Motility, 2014, 26, 108-114.	1.6	15
33	Weak Peristalsis With Large Breaks Is Associated With Higher Acid Exposure and Delayed Reflux Clearance in the Supine Position in GERD Patients. American Journal of Gastroenterology, 2014, 109, 46-51.	0.2	85
34	<i><scp>L</scp>actobacillus rhamnosus</i> protects human colonic muscle from pathogen lipopolysaccharideâ€induced damage. Neurogastroenterology and Motility, 2013, 25, 984.	1.6	31
35	Gastrointestinal sensitivity and gastroesophageal reflux disease. Annals of the New York Academy of Sciences, 2013, 1300, 80-95.	1.8	12
36	Human colonic myogenic dysfunction induced by mucosal lipopolysaccharide translocation and oxidative stress. Digestive and Liver Disease, 2013, 45, 1011-1016.	0.4	12

#	Article	IF	Citations
37	Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World Journal of Gastroenterology, 2013, 19, 5029.	1.4	77
38	Gastro-esophageal reflux disease and obesity, where is the link?. World Journal of Gastroenterology, 2013, 19, 6536.	1.4	45
39	Gastroesophageal reflux disease: Update on inflammation and symptom perception. World Journal of Gastroenterology, 2013, 19, 6523.	1.4	64
40	Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World Journal of Gastroenterology, 2013, 19, 6529.	1.4	64
41	Plateletâ€activating factor and distinct chemokines are elevated in mucosal biopsies of erosive compared with nonâ€erosive reflux disease patients and controls. Neurogastroenterology and Motility, 2012, 24, 943.	1.6	22
42	Progesterone receptors and serotonin levels in colon epithelial cells from females with slow transit constipation. Neurogastroenterology and Motility, 2011, 23, 575-e210.	1.6	32
43	Esophageal disease: updated information on inflammation. Annals of the New York Academy of Sciences, 2011, 1232, 369-375.	1.8	9
44	Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. Neurogastroenterology and Motility, 2010, 22, 866.	1.6	26
45	Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterology and Motility, 2010, 22, 746-e219.	1.6	107
46	Intercellular space diameters of the oesophageal epithelium in NERD patients: Head to head comparison between light and electron microscopy analysis. Digestive and Liver Disease, 2009, 41, 9-14.	0.4	28
47	Impaired contractility of colonic muscle cells in a patient with chronic intestinal pseudo-obstruction. Digestive and Liver Disease, 2008, 40, 225-229.	0.4	5
48	Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid. Gut, 2008, 57, 1740-1741.	6.1	15
49	Effect of Acute Mucosal Exposure to Lactobacillus rhamnosus GG on Human Colonic Smooth Muscle Cells. Journal of Clinical Gastroenterology, 2008, 42, S185-S190.	1.1	36
50	Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut, 2007, 56, 815-820.	6.1	53
51	Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. Gut, 2007, 57, 443-447.	6.1	100
52	Effect of oesophagitis on proximal extent of gastro-oesophageal reflux. Neurogastroenterology and Motility, 2007, 19, 459-464.	1.6	15
53	Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with nonâ€erosive gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2007, 25, 629-636.	1.9	107
54	Effect of hiatal hernia on proximal oesophageal acid clearance in gastro-oesophageal reflux disease patients. Alimentary Pharmacology and Therapeutics, 2006, 23, 751-757.	1.9	46

#	Article	IF	CITATIONS
55	Short-term ursodeoxycholic acid treatment improves gallbladder bile turnover in gallstone patients: a randomized trial. Neurogastroenterology and Motility, 2005, 17, 680-686.	1.6	10
56	Effect of endoscopic augmentation of the lower oesophageal sphincter (Gatekeeper reflux repair) Tj ETQq0 0 0 r	gBT /Over	lock 10 Tf 50
57	Dilated Intercellular Spaces of Esophageal Epithelium in Nonerosive Reflux Disease Patients with Physiological Esophageal Acid Exposure. American Journal of Gastroenterology, 2005, 100, 543-548.	0.2	221
58	Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2003, 18, 605-613.	1.9	140
59	Outcome of endoscopic sphincterotomy in post cholecystectomy patients with sphincter of Oddi dysfunction as predicted by manometry and quantitative choledochoscintigraphy. Gut, 2002, 50, 665-668.	6.1	71
60	Ultrasonographic assessment of gallbladder bile exchanges in healthy subjects and in gallstone patients. Ultrasound in Medicine and Biology, 2001, 27, 1445-1450.	0.7	9